{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal AstroStem-V",
            "NStudiesAvail": 430108,
            "NStudiesFound": 25,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 25,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "measure level of TNFa in blood (pg/ml)",
                              "measure of IL-1 in the blood (pg/ml)",
                              "measure of IL-6 in the blood (pg/ml)",
                              "measure of CRP in the blood (mg/L)",
                              "measure of AB40 in the blood (pg/ml)",
                              "measure of AB42 in the blood (pg/ml)",
                              "volume change from screening",
                              "Change from baseline score; scores from 0 to 30, lower score indicates more severe dementia",
                              "Change from baseline score; scores from 0 to 53, lower score indicates greater functional impairment",
                              "Change from baseline score; total score range is 14 to 70, higher scores indicate more enjoyment and satisfaction with life",
                              "Change from baseline score; score ranges from 0 to 100, higher score indicates less impairment",
                              "Change from baseline score; scores range fro 0 to 3, higher scores indicates more severe impairment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Tumor necrosis factor-alpha",
                              "Interleukin-1",
                              "Interleukin-6",
                              "C-reactive protein",
                              "Amyloid beta 40",
                              "Amyloid beta 42",
                              "Volumetric changes in hippocampus, ventriculus, and whole brain",
                              "Mini Mental Status Exam",
                              "Alzheimer's disease Cooperative Study Activities of Daily Living",
                              "Quality of Life Enjoyment and Satisfaction Questionnaire",
                              "Altoida Neuro Motor Index",
                              "Clinical Dementia Rating Questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "week 0, change from baseline at week 13, change from baseline at week 52",
                              "week 0, change from baseline at week 13, change from baseline at week 52",
                              "week 0, change from baseline at week 13, change from baseline at week 52",
                              "week 0, change from baseline at week 13, change from baseline at week 52",
                              "week 0, change from baseline at week 13, change from baseline at week 52",
                              "week 0, change from baseline at week 13, change from baseline at week 52",
                              "screening, week 26 and 52",
                              "week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52",
                              "week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52",
                              "week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52",
                              "week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52",
                              "week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04228666"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change from baseline in SpO2 at every visit",
                              "Check survival status of the subject at Visit 6, 10(Week 4, 8 and Week 12 if follow-up is possible) and record the status on eCRF.",
                              "Check the duration of the ventilator retention, check when the ventilator treatment has been completed after the baseline.",
                              "Perform chest X-ray every week (W1-W12) after screening, baseline, and W1 followed by 2-week intervals (W1, W2, W4, W6, W8, W12). In addition, CT is measured at week baseline, W4, W8 and W12.",
                              "Check the SOFA score every week (W1-W12) after baseline, and W1 followed by 2-week intervals (W1, W2, W4, W6, W8, W12).\n\nChoose the worst of the six physiological measurements and score between 0 and 4 points each and check the total. If the measured value is more than 3 points, it is defined as organ failure.",
                              "The Real-time PCR (RT-PCR) test for COVID-19 is measured at 2-week intervals (W1-W12) from Screening, Baseline to W1, W2, W4, W6, W8 and W12."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "SpO2",
                              "Mortality rate",
                              "Ventilator treatment status",
                              "Improvement of pneumonia assessed by radiologic examination(Chest X-ray or CT)",
                              "SOFA score (Sequential Organ Failure Assessment)",
                              "2019 nCOV nucleic acid test"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From baseline to Week 12",
                              "Week 4, Week 8, and Week 12",
                              "From Week 1 to Week 12",
                              "From baseline to Week 12",
                              "From baseline to Week 12",
                              "From baseline to Week 12"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04527224"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "absence of upper/lower respiratory infection by hospitalization criteria",
                              "clinical lab evaluation of level of glucose in the blood (mg/dL)",
                              "clinical lab evaluation of level of calcium in the blood (mg/dL)",
                              "clinical lab evaluation of level of albumin in the blood (g/dL)",
                              "clinical lab evaluation of level of total protein in the blood (g/dL)",
                              "clinical lab evaluation of level of sodium in the blood (mol/L)",
                              "clinical lab evaluation of level of carbon dioxide in the blood (mmol/L)",
                              "clinical lab evaluation of level of potassium in the blood (mmol/L)",
                              "clinical lab evaluation of level of chloride in the blood (mmol/L)",
                              "clinical lab evaluation of level of BUN in the blood (mg/dL)",
                              "clinical lab evaluation of level of creatinine in the blood (mg/dL)",
                              "clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)",
                              "clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)",
                              "clinical lab evaluation of level of aspartate aminotransferase in the blood (IU/L)",
                              "clinical lab evaluation of level of total bilirubin in the blood (mg/dL)",
                              "clinical lab evaluation of level of white blood cells in the blood (x 10^3/uL)",
                              "clinical lab evaluation of level of red blood cells in the blood (x 10^6/uL)",
                              "clinical lab evaluation of level of hemoglobin in the blood (g/dL)",
                              "clinical lab evaluation of level of hematocrit in the blood (%)",
                              "clinical lab evaluation of mean corpuscular volume in the blood (fL)",
                              "clinical lab evaluation of mean corpuscular hemoglobin in the blood (pg)",
                              "clinical lab evaluation of mean corpuscular hemoglobin in the blood (g/dL)",
                              "clinical lab evaluation of red blood cell distribution width in the blood (%)",
                              "clinical lab evaluation of neutrophils in the blood (%)",
                              "clinical lab evaluation of lymphocytes in the blood (%)",
                              "clinical lab evaluation of monocytes in the blood (%)",
                              "clinical lab evaluation of eosinophils in the blood (%)",
                              "clinical lab evaluation of basophils in the blood (%)",
                              "clinical lab evaluation of absolute neutrophils in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute lymphs in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute monocytes in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute eosinophils in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute basophils in the blood (x 10^3/uL)",
                              "clinical lab evaluation of granulocytes in the blood (%)",
                              "clinical lab evaluation of granulocytes in the blood (x 10^3/uL)",
                              "clinical lab evaluation of platelets in the blood (x 10^3/uL)",
                              "clinical lab evaluation of time for blood to coagulate (seconds)",
                              "clinical lab evaluation of international normalized ratio of blood coagulation (no unit)",
                              "clinical lab evaluation of tumor necrosis factor alpha in the blood (pg/mL)",
                              "clinical lab evaluation of interleukin-6 in the blood (pg/mL)",
                              "clinical lab evaluation of interleukin-10 in the blood (pg/mL)",
                              "clinical lab evaluation of interleukin-10 in the blood (mg/L)",
                              "Short-form 36 Health Survey; scored on a scale of 0-100; lower score equals more disability.",
                              "Depression module; scores DSM-IV criteria 0-3 to monitor severity of depression."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "absence of upper/lower respiratory infection",
                              "Glucose",
                              "Calcium",
                              "Albumin",
                              "Total Protein",
                              "Sodium",
                              "Total carbon dioxide",
                              "Potassium",
                              "Chloride",
                              "BUN",
                              "Creatinine",
                              "Alkaline phosphatase",
                              "Alanine aminotransferase",
                              "Aspartate aminotransferase",
                              "Total bilirubin",
                              "White blood cells",
                              "Red blood cells",
                              "Hemoglobin",
                              "Hematocrit",
                              "Mean corpuscular volume",
                              "Mean corpuscular hemoglobin",
                              "Mean corpuscular hemoglobin concentration",
                              "Red cell distribution width",
                              "Neutrophils",
                              "Lymphs",
                              "Monocytes",
                              "Eos",
                              "Basophils",
                              "Absolute neutrophils",
                              "Absolute lymphs",
                              "Absolute monocytes",
                              "Absolute eosinophils",
                              "Absolute basophils",
                              "Immature granulocytes",
                              "Absolute Immature granulocytes",
                              "Platelets",
                              "Prothrombin time",
                              "INR",
                              "TNFalpha",
                              "Interleukin-6",
                              "Interleukin-10",
                              "C-reactive protein",
                              "SF-36",
                              "PHQ-9"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Weeks 0 through 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26",
                              "Weeks 0, 6, 14, 26"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04349631"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [
                              "August 19, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "February 24, 2022"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Tumor Necrosis factor (TNF-a) (pg/mL) measured during trial.",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of interleukin 6 (IL-6) (pg/mL) during the trial",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of C-reactive protein (CRP) (mg/L) during the trial",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of erythrosedimentation rate (ESR) (mm/hr) during the trial.",
                              "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Joint Count 66/68 (# joints - tender and swollen) during the trial."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The Effect of Single Injection of HB-adMSCs on TNF-a in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on IL-6 in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on CRP in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on ESR in Patients With Acute RA",
                              "The Effect of Single Injection of HB-adMSCs on Joint Count in Patients With Acute RA."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT03691909"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04087889"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2019-002688-89"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "SOFA index from 0 to 4 where lower scores represent improvement",
                              "Murray scale from 0 to 4 where lower scores represent improvement"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040",
                              "Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040",
                              "Mechanical ventilation-free days 28 days after the administration of HCR040",
                              "Percent mortality 28 days after the administration of HCR040",
                              "Daily pulmonary mechanics values (Ppl, DP, CRS)",
                              "Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040",
                              "Vasopressor-free days 28 days after the administration of HCR040",
                              "ICU-free days 28 days after the administration of HCR040"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "Day 28",
                              "One year",
                              "Day 28",
                              "Day 28",
                              "Day 28"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of subjects that develop upper/lower respiratory infection with hospitalization criteria",
                              "change from baseline in leukocyte differential",
                              "change from baseline in C Reactive protein",
                              "change from baseline in TNF alpha",
                              "change from baseline in IL-6",
                              "change from baseline in IL-10",
                              "clinical lab evaluation of level of glucose in the blood (mg/dL)",
                              "clinical lab evaluation of level of calcium in the blood (mg/dL)",
                              "clinical lab evaluation of level of albumin in the blood (g/dL)",
                              "clinical lab evaluation of level of total protein in the blood (g/dL)",
                              "clinical lab evaluation of level of sodium in the blood (mol/L)",
                              "clinical lab evaluation of level of total carbon dioxide in the blood (mmol/L)",
                              "clinical lab evaluation of level of potassium in the blood (mmol/L)",
                              "clinical lab evaluation of level of chloride in the blood (mmol/L)",
                              "clinical lab evaluation of level of BUN in the blood (mg/dL)",
                              "clinical lab evaluation of level of creatinine in the blood (mg/dL)",
                              "clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)",
                              "clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)",
                              "clinical lab evaluation of level of total bilirubin in the blood (mg/dL)",
                              "clinical lab evaluation of level of white blood cells in the blood (x 10^3/uL)",
                              "clinical lab evaluation of level of red blood cells in the blood (x 10^6/uL)",
                              "clinical lab evaluation of level of hemoglobin in the blood (g/dL)",
                              "clinical lab evaluation of level of hematocrit in the blood (%)",
                              "clinical lab evaluation of mean corpuscular volume in the blood (fL)",
                              "clinical lab evaluation of mean corpuscular hemoglobin in the blood (pg)",
                              "clinical lab evaluation of mean corpuscular hemoglobin concentration in the blood (g/dL)",
                              "clinical lab evaluation of red cell distribution width in the blood (%)",
                              "clinical lab evaluation of neutrophils in the blood (%)",
                              "clinical lab evaluation of lymphocytes in the blood (%)",
                              "clinical lab evaluation of monocytes in the blood (%)",
                              "clinical lab evaluation of eosinophils in the blood (%)",
                              "clinical lab evaluation of basophils in the blood (%)",
                              "clinical lab evaluation of absolute neutrophils in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute lymphocytes in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute monocytes in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute eosinophils in the blood (x 10^3/uL)",
                              "clinical lab evaluation of absolute basophils in the blood (x 10^3/uL)",
                              "clinical lab evaluation of immature granulocytes in the blood (x 10^3/uL)",
                              "clinical lab evaluation of platelets in the blood (x 10^3/uL)",
                              "clinical lab evaluation of time for blood to coagulate (seconds)",
                              "clinical lab evaluation of international normalized ratio of blood coagulation (no unit)",
                              "Short-form 36 Health Survey; scored on a scale of 0-100; lower score equals more disability",
                              "Depression module; scores DSM-IV criteria 0-3 to monitor severity of depression"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Absence of upper/lower respiratory infection",
                              "Leukocyte differential",
                              "C Reactive protein",
                              "TNF alpha",
                              "IL-6",
                              "IL-10",
                              "Glucose",
                              "Calcium",
                              "Albumin",
                              "Total protein",
                              "Sodium",
                              "Total carbon dioxide",
                              "Potassium",
                              "Chloride",
                              "BUN",
                              "Creatinine",
                              "Alkaline phosphatase",
                              "Alanine aminotransferase",
                              "Total bilirubin",
                              "white blood cells",
                              "red blood cells",
                              "hemoglobin",
                              "hematocrit",
                              "mean corpuscular volume",
                              "mean corpuscular hemoglobin",
                              "mean corpuscular hemoglobin concentration",
                              "red cell distribution width",
                              "neutrophils",
                              "Lymphs",
                              "Monocytes",
                              "Eosinophils",
                              "Basophils",
                              "Absolute neutrophils",
                              "Absolute lymphs",
                              "Absolute monocytes",
                              "Absolute eosinophils",
                              "Absolute basophils",
                              "Immature granulocytes",
                              "Platelets",
                              "Prothrombin time",
                              "INR",
                              "SF-36",
                              "PHQ-9"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "week 0 through week 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26",
                              "weeks 0, 6, 14, 26"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04348435"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03925649"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Monitoring for changes in qt interval",
                              "change from baseline in leukocyte differential",
                              "clinical lab evaluation of level of glucose in the blood (mg/dL)",
                              "clinical lab evaluation of level of calcium in the blood (mg/dL)",
                              "clinical lab evaluation of level of albumin in the blood (g/dL)",
                              "clinical lab evaluation of level of total protein in the blood (g/dL)",
                              "clinical lab evaluation of level of sodium in the blood (mol/L)",
                              "clinical lab evaluation of level of total carbon dioxide in the blood (mmol/L)",
                              "clinical lab evaluation of level of potassium in the blood (mmol/L)",
                              "clinical lab evaluation of level of chloride in the blood (mmol/L)",
                              "clinical lab evaluation of level of BUN in the blood (mg/dL)",
                              "clinical lab evaluation of level of creatinine in the blood (mg/dL)",
                              "clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)",
                              "clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)",
                              "clinical lab evaluation of level of total bilirubin in the blood (mg/dL)",
                              "clinical lab evaluation of level of white blood cells in the blood (x10^3/uL)",
                              "clinical lab evaluation of level of red blood cells in the blood (x10^6/uL)",
                              "clinical lab evaluation of level of hemoglobin in the blood (g/dL)",
                              "clinical lab evaluation of level of hematocrit in the blood (%)",
                              "clinical lab evaluation of level of mean corpuscular volume in the blood (fL)",
                              "clinical lab evaluation of level of mean corpuscular hemoglobin in the blood (pg)",
                              "clinical lab evaluation of level of mean corpuscular hemoglobin concentration in the blood (g/dL)",
                              "clinical lab evaluation of level of red cell distribution width in the blood (%)",
                              "clinical lab evaluation of level of neutrophils in the blood (%)",
                              "clinical lab evaluation of level of lymphocytes in the blood (%)",
                              "clinical lab evaluation of level of monocytes in the blood (%)",
                              "clinical lab evaluation of level of eosinophils in the blood (%)",
                              "clinical lab evaluation of level of basophils in the blood (%)",
                              "clinical lab evaluation of level of absolute neutrophils in the blood (x10^3/uL)",
                              "clinical lab evaluation of level of absolute lymphocytes in the blood (x10^3/uL)",
                              "clinical lab evaluation of level of absolute monocytes in the blood (x10^3/uL)",
                              "clinical lab evaluation of level of absolute eosinophils in the blood (x10^3/uL)",
                              "clinical lab evaluation of level of absolute basophils in the blood (x10^3/uL)",
                              "clinical lab evaluation of level of immature granulocytes in the blood (x10^3/uL)",
                              "clinical lab evaluation of level of platelets in the blood (x10^3/uL)",
                              "clinical lab evaluation of time for blood to coagulate (seconds)",
                              "clinical lab evaluation of international normalized ratio of blood coagulation (no unit)",
                              "clinical lab evaluation of percentage of cells CD3- and CD54+ (%)",
                              "clinical lab evaluation of ratio of CD4+ cells to CD8+ cells (no unit)",
                              "clinical lab evaluation of level of myoglobin in the blood (ng/mL)",
                              "clinical lab evaluation of level of myoglobin in the blood (ng/mL)",
                              "clinical lab evaluation of level of creatinine kinase in the blood (U/L)",
                              "clinical lab evaluation of level of serum ferritin in the blood (ng/mL)",
                              "incidence of adverse events",
                              "change from baseline in ordinal scale score; scale of 1-7; a score of 1 indicates death and 7 indicates subject is not hospitalized and has no limitations on activities.",
                              "change from baseline in D-dimer",
                              "change from baseline chest x-ray result",
                              "change from baseline CT scan result",
                              "time to achieve negative PCR test results"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "EKG qt interval",
                              "Leukocyte differential",
                              "Glucose",
                              "Calcium",
                              "Albumin",
                              "Total protein",
                              "Sodium",
                              "Total carbon dioxide",
                              "Potassium",
                              "Chloride",
                              "BUN",
                              "Creatinine",
                              "Alkaline phosphatase",
                              "Alanine aminotransferase",
                              "Total bilirubin",
                              "White blood cells",
                              "Red blood cells",
                              "Hemoglobin",
                              "Hematocrit",
                              "Mean corpuscular volume",
                              "Mean corpuscular hemoglobin",
                              "Mean corpuscular hemoglobin concentration",
                              "Red cell distribution width",
                              "Neutrophils",
                              "Lymphs",
                              "Monocytes",
                              "Eosinophils",
                              "Basophils",
                              "Absolute neutrophils",
                              "Absolute lymphs",
                              "Absolute monocytes",
                              "Absolute eosinophils",
                              "Absolute basophils",
                              "Immature granulocytes",
                              "Platelets",
                              "Prothrombin time",
                              "INR",
                              "NK cell surface antigen (CD3-CD54+)",
                              "CD4+/CD8+ ratio",
                              "Myoglobin",
                              "Troponin",
                              "Creatinine kinase MB",
                              "Serum ferritin",
                              "Adverse events",
                              "7-point ordinal scale",
                              "D-dimer",
                              "Chest X-ray",
                              "CT scan",
                              "PCR test for SARS-CoV-2"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "screening, day 0, 3, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening, day 0, 7, 10",
                              "screening through day 28",
                              "screening, day 0, 3, 7, 10, 28",
                              "screening, day 0, 7, 10",
                              "Day 0, Day 28",
                              "Day 0, Day 28",
                              "day 0, 3, 7, 10"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04362189"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Hope Biosciences"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.hope.bio"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04029896"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes in MDS-UPDRS Part I",
                              "Changes in Total score MDS-UPDRS Part II and Part III",
                              "Changes in MDS-UPDRS Part III",
                              "Changes in MDS-UPDRS Part IV",
                              "Changes in SF-36",
                              "Improvements in Participants PFS-16 scores",
                              "Improvements in Participants PDQ-39 scores",
                              "Changes in Participants VAS Pain Scales",
                              "Changes in Participants VAS spasms Scale",
                              "Changes in Participants medications taken"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.",
                              "19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.",
                              "20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.",
                              "21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.",
                              "22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).",
                              "23. Changes in Parkinson's disease fatigue scale (PFS-16)",
                              "24. Changes in Parkinson's disease Questionnaire (PDQ-39).",
                              "25. Changes in Visual Analog Scale for Pain.",
                              "26. Changes in Visual Analog Scale for Muscle spasms.",
                              "27. Changes in Dosage of medications taken to treat Parkinson's disease."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04995081"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "DTI to assess macro- and micro-structural properties",
                              "[11C]ER-176 tracer/label to identify brain proteins associated with neuroinflammatory response regulation",
                              "Dichotomized-Glasgow Outcomes Score (GOSE) to evaluate affect, functional outcome, and neuropsychological function",
                              "Galveston Orientation and Amnesia Test (GOAT) evaluation of cognition",
                              "Rivermead Post-Concussion Symptoms Questionnaire (RPSQ) evaluation to identify presence and severity of concussive symptoms",
                              "Automated Neuropsychological Assessment Metrics (ANAM) evaluation of attention, concentration, reaction time, memory, processing speed, and decision-making",
                              "Verbal Selective Reminding Test (VSRT) to evaluate verbal learning and memory",
                              "Verbal Fluency Test (VFT) to evaluate vocabulary size, lexical access speed, updating, and inhibition ability",
                              "Stroop to evaluate selective attention and cognitive flexibility",
                              "measure IL-1\u03b1 via a bead-based, flow cytometric ELISA for the cytokines",
                              "measure IL-4 via a bead-based, flow cytometric ELISA for the cytokines",
                              "measure TNF\u03b1 via a bead-based, flow cytometric ELISA for the cytokines",
                              "measure IL-6 via a bead-based, flow cytometric ELISA for the cytokines",
                              "measure IL-10 via a bead-based, flow cytometric ELISA for the cytokines",
                              "measure concentration of albumin via BCG immunochemical analysis"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Whole brain MRI",
                              "PET/DT-MRI",
                              "Glasgow Outcome Score",
                              "Galveston Orientation and Amnesia Test",
                              "Rivermead Post-Concussion Symptoms Questionnaire",
                              "Automated Neuropsychological Assessment Metrics",
                              "Verbal Selective Reminding Test",
                              "Verbal Fluency Test",
                              "Stroop",
                              "Interleukin 1-alpha",
                              "Interleukin 4",
                              "Tumor necrosis factor alpha",
                              "Interleukin 6",
                              "Interleukin 10",
                              "Albumin"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, change from baseline at 6 months post-infusion",
                              "Baseline, change from baseline at 6 months post-infusion",
                              "Baseline, change from baseline at Imaging visit #2, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion",
                              "Baseline, change from baseline at Imaging visit #2, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion",
                              "Baseline, change from baseline at Imaging visit #2, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion",
                              "Baseline, change from baseline at Imaging visit #2, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion",
                              "Baseline, change from baseline at Imaging visit #2, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion",
                              "Baseline, change from baseline at Imaging visit #2, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion",
                              "Baseline, change from baseline at Imaging visit #2, change from baseline at 6 months post-infusion, change from baseline at 1 year post-infusion",
                              "Baseline, change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion",
                              "Baseline, change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion",
                              "Baseline, change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion",
                              "Baseline, change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion",
                              "Baseline, change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion",
                              "Baseline, change from baseline at 6 months post-infusion, change from baseline 1 year post-infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04063215"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The EDSS is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. This scale ranges from 0 to 10 in 0.5-unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist.",
                              "The Barthel index is an ordinal scale that evaluates functional independence in the domains of personal care and mobility. A total of ten variables describing activities of daily living and mobility are considered, with a higher number reflecting better capacity to operate independently. The Barthel Index assesses the level of help needed by a person on a set of ten activities of daily living (ADL) related to mobility and self-care.",
                              "The 9-HPT is a short, standardized upper extremity exam. It measures the time taken to complete the test activity, recorded in seconds. The higher the score the worse the disability.",
                              "The PHQ-9 is the most used depression and suicidal thoughts screening test used to monitor the severity of depression and response to treatment.\n\nDepression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe.",
                              "Incidence and risk of AEs of special interest (serious or non-serious), including thromboembolic events, peripheral events defined as, thromboembolism of the extremities, also infections and hypersensitivities."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Expanded Disability Status Scale (EDSS)",
                              "To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Barthel Index",
                              "To determine the efficacy of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in 9-Hole Peg Test",
                              "To identify the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in Patient Health Questionnaire (PHQ-9)",
                              "To assess the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by the incidence of adverse events or serious adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52",
                              "Baseline to Week 52"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05116540"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Hope Biosciences"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.hope.bio"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04064957"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "MDS-UPDS Parts I, II, III and IV.",
                              "Non-Motor Aspects of Experiences of Daily Living (nM-EDL), including complex behaviors such as, cognitive impairment, hallucinations and psychosis, depressed mood, anxious mood, apathy, features of dopamine dysregulation syndrome, sleep problems, daytime sleepiness, pain and other sensations, urinary problems, constipation problems, light headedness on standing and fatigue.",
                              "Motor Examination, including speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination movements of hands, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, global spontaneity of movement (body bradykinesia), postural tremor of the hands, kinetic tremor of the hands, rest tremor amplitude, constancy of rest tremor, dyskinesias impact and Hoehn and Yahr stage.",
                              "Motor Complications, including time spent with dyskinesias and others.",
                              "Communication - Short Form",
                              "Ability to Participate in Social Roles and Activities - Short Form",
                              "Anxiety - Short Form",
                              "Depression - Short Form",
                              "Emotional and Behavioral Dyscontrol - Short Form",
                              "Fatigue - Short Form",
                              "Lower Extremity Function (Mobility) - Short Form",
                              "Positive Affect and Well-Being - Short Form",
                              "Sleep Disturbance - Short Form",
                              "Upper Extremity Function (Fine Motor, ADL) - Short Form",
                              "Stigma-Short Form",
                              "Satisfaction with Social Roles and Activities - Short Form",
                              "Cognition Function- Short Form",
                              "Score of \u22658 indicates the presence of significant fatigue.",
                              "Difficulties across the 8 quality of life dimensions of functioning of wellbeing.",
                              "Visual Analog Scale for Pain.",
                              "Dosage of medications.",
                              "Adverse Event (TEAEs)",
                              "Including thromboembolic events, peripheral events defined as, thromboembolism of the extremities, also infections and hypersensitivities.",
                              "CBC",
                              "Visual Analog Scale for muscle spasms.",
                              "Changes in Respiratory Rate.",
                              "Changes in Heart Rate.",
                              "Changes in Body Temperature.",
                              "Changes in Blood Pressure.",
                              "Changes in Oxygen Saturation.",
                              "Physical examination results.",
                              "Weight in lb.",
                              "CMP",
                              "Coagulation Panel"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in MDS-UPDS total score.",
                              "Changes in MDS-UPDRS Part I.",
                              "Changes in MDS-UPDRS Part III.",
                              "Changes in MDS-UPDRS Part IV.",
                              "Changes in Neuro-QOL. - Communication",
                              "Changes in Neuro-QOL. - Social Roles and Activities",
                              "Changes in Neuro-QOL. - Anxiety",
                              "Changes in Neuro-QOL. - Depression",
                              "Changes in Neuro-QOL. - Dyscontrol",
                              "Changes in Neuro-QOL. - Fatigue",
                              "Changes in Neuro-QOL. - Mobility",
                              "Changes in Neuro-QOL. - Well-Being",
                              "Changes in Neuro-QOL. - Sleep",
                              "Changes in Neuro-QOL. - Fine Motor",
                              "Changes in Neuro-QOL. - Stigma",
                              "Changes in Neuro-QOL. - Social Roles",
                              "Changes in Neuro-QOL. - Cognition",
                              "Changes in Parkinson's disease fatigue scale (PFS-16).",
                              "Changes in Parkinson's disease Questionnaire (PDQ-39).",
                              "Changes in Visual Analog Scale for Pain.",
                              "Changes in Dosage of medications taken to treat Parkinson's disease.",
                              "Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).",
                              "Incidence and risk of AEs of special interest (serious or non-serious),",
                              "Clinically significant changes in laboratory values. - CBC",
                              "Changes in Visual Analog Scale for muscle spasms.",
                              "Clinically significant changes in vital signs. - Respiratory Rate",
                              "Clinically significant changes in vital signs. - Heart Rate",
                              "Clinically significant changes in vital signs. - Body Temperature.",
                              "Clinically significant changes in vital signs. - Blood Pressure.",
                              "Clinically significant changes in vital signs. - Oxygen Saturation.",
                              "Clinically significant changes in physical examination results.",
                              "Clinically significant changes in weight in lb.",
                              "Clinically significant changes in laboratory values. - CMP",
                              "Clinically significant changes in laboratory values. - Coagulation Panel"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.",
                              "Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04928287"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04604288"
                        ]
                  },
                  {
                        "Rank": 17,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Clinically significant changes in Fatigue Assessment form.",
                              "Clinically significant changes in Dyspnea a rest",
                              "Clinically significant changes in Dyspnea with activity",
                              "Clinically significant changes in Cough",
                              "Clinically significant changes in Body aches",
                              "Clinically significant changes in Joint pain",
                              "Clinically significant changes in Short Form 36 Health Survey Questionnaire pain",
                              "Clinically significant changes in PHQ 9 scale. pain"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in Subject's energy - Fatigue Assessment form.",
                              "Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea a rest",
                              "Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea with activity",
                              "Changes in Visual Analog Scale of non -Neurological Symptoms. - Cough",
                              "Changes in Visual Analog Scale of non -Neurological Symptoms. - Body aches",
                              "Changes in Visual Analog Scale of non -Neurological Symptoms. - Joint pain",
                              "Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire",
                              "Changes in Subject's level of depression - PHQ 9 scale."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to Weeks 26",
                              "Baseline to Weeks 26",
                              "Baseline to Weeks 26",
                              "Baseline to Weeks 26",
                              "Baseline to Weeks 26",
                              "Baseline to Weeks 26",
                              "Baseline to Weeks 26",
                              "Baseline to Weeks 26"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05126563"
                        ]
                  },
                  {
                        "Rank": 18,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04514952"
                        ]
                  },
                  {
                        "Rank": 19,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Hope Biosciences Stem Cell Research Foundation"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.hopebio.org/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04772378"
                        ]
                  },
                  {
                        "Rank": 20,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Hope Biosciences LLC",
                              "Hope Biosciences Stem Cell Research Foundation"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.hope.bio/",
                              "https://www.hopebio.org/"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04798066"
                        ]
                  },
                  {
                        "Rank": 21,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04711811"
                        ]
                  },
                  {
                        "Rank": 22,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04825626"
                        ]
                  },
                  {
                        "Rank": 23,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04825613"
                        ]
                  },
                  {
                        "Rank": 24,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04064983"
                        ]
                  },
                  {
                        "Rank": 25,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05154851"
                        ]
                  }
            ]
      }
}